Related Experiment Video
Updated: Mar 25, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other
M F Sanmamed1, C Chester2, I Melero3
1Department of Immunobiology, Yale University School of Medicine, New Haven miguel.sanmamed@yale.edu.
Abstract:
The recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically, anticancer therapeutics have been tested in syngeneic mouse models (with a fully murine immune system) or in immunodeficient mice that allow the engraftment of human xenografts. Animal models with functioning human immune systems are critically needed to more accurately recapitulate the complexity of the human tumor microenvironment. Such models are integral to better predict tumor responses to both immunomodulatory agents and directly antineoplastic therapies. In this regard, the development of humanized models is a promising, novel strategy that offers the possibility of testing checkpoint blockers' capacity and their combination with other antitumor drugs. In this review, we discuss the strengths and weaknesses of the available animal models regarding their capacity to evaluate checkpoint blockers and checkpoint blocker-based combination immunotherapy.
Insights
Humanized animal models are essential for accurately testing cancer immunotherapies, particularly checkpoint blockers. These models improve prediction of treatment responses compared to traditional methods.
Area of Science:
- Immunology
- Oncology
- Preclinical Research
Background:
- Checkpoint blockers have shown success in cancer treatment, highlighting the immune system's role.
- Current preclinical models (syngeneic, xenograft) have limitations in recapitulating the human immune response to cancer.
- There is a critical need for animal models that incorporate a functioning human immune system.
Purpose of the Study:
- To review the strengths and weaknesses of current animal models for evaluating cancer immunotherapies.
- To discuss the utility of humanized models in assessing checkpoint blockers and combination therapies.
- To highlight the importance of appropriate models for predicting clinical outcomes.
Main Methods:
- Review of existing literature on syngeneic, xenograft, and humanized mouse models.
- Analysis of model capabilities in evaluating immunomodulatory agents, specifically checkpoint blockers.
- Assessment of models for predicting responses to combination immunotherapies.
Main Results:
- Syngeneic and xenograft models offer insights but do not fully represent the human tumor microenvironment.
- Humanized models provide a more accurate platform for studying human immune responses to cancer therapies.
- Humanized models are crucial for evaluating the efficacy and potential toxicities of checkpoint blockers and combination treatments.
Conclusions:
- Humanized animal models are indispensable for advancing cancer immunotherapy research.
- These models enhance the predictive power of preclinical studies for checkpoint blocker efficacy.
- Further development and validation of humanized models are critical for optimizing cancer treatment strategies.
More Related Videos
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:27Tumor Immunotherapy